Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - INNOVUS PHARMACEUTICALS, INC.ex32-2.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - INNOVUS PHARMACEUTICALS, INC.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - INNOVUS PHARMACEUTICALS, INC.ex31-1.htm
EX-23.1 - CONSENTS OF EXPERTS AND COUNSEL - INNOVUS PHARMACEUTICALS, INC.ex23-1.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - INNOVUS PHARMACEUTICALS, INC.ex21-1.htm
EX-14.1 - CODE OF ETHICS - INNOVUS PHARMACEUTICALS, INC.ex14-1.htm
10-K - ANNUAL REPORT - INNOVUS PHARMACEUTICALS, INC.innv10k_dec312017.htm
 
Exhibit 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Innovus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassam Damaj, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
 
 
Date: April 2, 2018
/s/ Bassam Damaj
 
Bassam Damaj, Ph.D.
 
President and Chief Executive Officer
 
(Principal Executive Officer)